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Beyond the BET family: targeting CBP/p300 with 4-acyl pyrroles 
Martin Hügle, Xavier Lucas, Dmytro Ostrovskyi, Pierre Regenass, Stefan Gerhardt, Oliver Einsle, 
Mirjam Hau, Manfred Jung, Bernhard Breit, Stefan Günther and Daniel Wohlwend* 
 
Abstract: BET bromodomain inhibitors are widely used both as 
chemical tools to study the biological role of their targets in living 
organisms, and as candidates for drug development against several 
cancer variants and human disorders. However, non-BET 
bromodomains such as those in p300 and CBP are less studied. Here, 
we introduce XDM-CBP, a highly potent and selective inhibitor for the 
bromodomains of CBP and p300 derived from a pan-selective BET 
BRD-binding fragment. In addition to X-ray crystal structure analysis 
and thermodynamic profiling, we used XDM-CBP in in vitro cell 
screenings of several cancer cell lines to study its inhibitory potential 
on cancer cell proliferation. Our results demonstrate that XDM-CBP 
is a potent and selective CBP/p300 inhibitor that acts on specific 
cancer cell lines, in particular malignant melanoma, breast cancer, 
and leukemia. 
Small molecules inhibiting bromodomains (BDs) represent not 
only a novel approach to addressing specific malignancies driven 
or controlled by the epigenetic machinery, but also a valuable tool 
to study fundamental epigenetic mechanisms by means of 
chemical probes.[1] Most studies and drug discovery campaigns, 
however, focus on six members of the bromodomain and extra-
terminal domain (BET) family. Especially, BRD4 is a proven drug 
target for fighting cancer, atherosclerosis, or diabetes.[2] Recently, 
great efforts have been made to identify inhibitors for BDs beyond 
the BET class.[2] In particular, the BD-containing cAMP response 
element-binding protein binding protein (CBP, also CREBBP) was 
shown to have a great potential for cancer treatment.[3] CBP and 
the close homologue E1A binding protein p300 (p300) co-activate 
transcription by bridging specific transcription factors with the 
basal transcription machinery.[4] They are also involved in 
chromatin relaxation through their histone acetyltransferase 
activity.[4] Similarly, they can directly acetylate transcription 
factors and thus modulate their activity. Finally, through their 
multiple domains, both proteins recruit a variety of proteins of the 
tumor immune response that moved them into the focus of 
oncology research.[5] 
Within recent years four scaffolds could be identified that 
inhibit the BDs of CBP and p300 with nanomolar binding affinity 
(Supporting Table S1). In 2014, the first nanomolar CBP inhibitor 
scaffold was published, showing weak selectivity against 
BRD4(1) (KD,CBP = 390 nM, KD, BRD4 = 1.4 µM, determined by 
isothermal titration calorimetry, ITC).[6] The chemical probe SGC-
CBP30 belongs to a second class of CBP inhibitors (KD = 21 nM, 
ITC) and is highly selective, although significant affinity was also 
observed to BRD4(1) (KD = 850 nM, ITC).[7] This scaffold was 
optimized by Pfizer to give PF-CBP1 (KD,CBP = 190 nM, KD,BRD4 > 
20 µM, ITC, >100-fold selectivity). PF-CBP1 downregulates a 
number of inflammatory genes in macrophages as well as neuron 
specific genes, suggesting a therapeutic opportunity for CBP 
inhibitors in the treatment of neurological disorders.[8] I-CBP-112 
belongs to the third CBP-inhibitor class (KD, CBP = 151 nM, KD,BRD4 
= 5.6 µM, ITC, 40-fold selectivity).[3] It notably reduces the 
leukemia-initiating potential of AML cells in vitro and in vivo. Most 
recently, Unzue and co-workers[9] presented a molecule with 33-
fold selectivity (KD,CBP = 300 nM, ITC, KD,BRD4(1) = 9.9 µM, by 
competition assay) that acts on leukemia cell lines. 
In this study we examined the inhibitory potential of fragments 
of our recently developed 4-acyl pyrrole based potent BET-
inhibitor XD14[10] on CBP/p300. The core fragment XD46 still 
showed substantial affinity towards the BET family[11] but equally 
addressed CBP and p300 (Figure 1, Supporting Figure S1). 
Consequently, we set out to direct the selectivity of XD46 
derivatives away from the BET family toward CBP/p300 using a 
combination of computational methods, chemical syntheses, X-
ray crystallography, and ITC. 
We initially grew XD46 inside the recognition site of p300 in 
silico and identified XDM1 (Figure 1) with a m-chlorobenzyl 
attached to the amide anchor of XD46 (Syntheses for all 
compounds are given in the Supplementary Information). XDM1 
[a] Dr. D. Wohlwend 
Institut für Biochemie 
Albert-Ludwigs-Universität Freiburg 
Albertstr. 21, D-79104 Freiburg (Germany) 
E-mail: wohlwend@bio.chemie.uni-freiburg.de  
Prof. Dr. S. Günther 
Institut für Pharmazeutische Wissenschaften and Freiburg Institute 
for Advanced Studies (FRIAS)  
Albert-Ludwigs-Universität Freiburg 
Hermann-Herder-Str. 9, D-79104 Freiburg (Germany) 
E-mail: stefan.guenther@pharmazie.uni-freiburg.de  
[b] M. Hügle,[+] Dr. S. Gerhardt 
Institut für Biochemie 
Albert-Ludwigs-Universität Freiburg 
Albertstr. 21, D-79104 Freiburg (Germany)  
Dr. X. Lucas[+] 
School of Life Sciences, Division of Biological Chemistry and Drug 
Discovery  
University of Dundee, James Black Centre 
Dow Street, Dundee, DD1 5EH (United Kingdom) 
Prof. Dr. O. Einsle 
Institut für Biochemie, Freiburg Institute for Advanced Studies 
(FRIAS) and BIOSS Centre for Biological Signalling Studies 
Albert-Ludwigs-Universität Freiburg 
Albertstr. 21, D-79104 Freiburg (Germany)  
Dr. D. Ostrovskyi,[+] Dr. P. Regenass 
Institut für Organische Chemie 
Albert-Ludwigs-Universität Freiburg 
Albertstr. 21, D-79104 Freiburg (Germany) 
Prof. Dr. B. Breit  
Institut für Organische Chemie and Freiburg Institute for Advanced 
Studies (FRIAS) 
Albert-Ludwigs-Universität Freiburg 
Albertstr. 21, D-79104 Freiburg (Germany) 
M. Hau, Prof. Dr. M. Jung  
Institut für Pharmazeutische Wissenschaften 
Albert-Ludwigs-Universität Freiburg 
Albertstr. 25, D-79104 Freiburg (Germany) 
 
 
[+] These authors contributed equally to this work 
 Supporting information for this article is given via a link at the end of 
the document 
10.1002/anie.201705516Angewandte Chemie International Edition
This article is protected by copyright. All rights reserved.





has moderate affinity to both targets, slightly favoring p300 over 
CBP (Supporting Figure S2). 
Figure 1. Chemical structures of compounds explored during the development of XDM-CBP based on fragment XD46. KD values were determined by ITC. 
The crystal structure of XDM1 in complex with CBP (Figure 
2A) confirmed that it binds to the recognition pocket of CBP with 
five well-conserved water molecules surrounding its 4-acyl pyrrole 
core.[12] In addition, the structure presents an induced-fit binding 
mode of Pro1110 and Arg1173.[6] As setting up this cavity 
depends on binding of a suitable ligand, we designate this motif 
the inducible RP cavity. In complex with p300, XDM1 presents a 
similar yet more heterogeneous binding, exemplified by three 
slightly different binding modes (Supporting Figure S12). Analysis 
of the crystal structures of XDM1 with both p300 and CBP using 
SiteMap (Schrödinger, LLC, New York, NY, USA) revealed a 
hydrophobic region within the ZA channel (Supporting Figure 
S13). To address it and at the same time reduce the flexibility of 
the chlorobenzyl moiety, we next introduced a 7-chloro-1,2,3,4-
tetrahydronaphthalenyl moiety, thus fixing the m-chlorobenzyl 
system (XDM2, Figure 1). The two resulting enantiomers, XDM2a 
and XDM2b, were separated by means of chiral HPLC and 
characterized by ITC (Supporting Figures S3-4). XDM2a lost 
affinity and fell back to the level of the starting fragment XD46. 
XDM2b exhibited an apparent 59-fold selectivity toward p300 
over CBP, primarily by losing affinity toward the latter (Figure 1). 
However, both molecules lacked an adequate solubility due to 
their increased hydrophobicity (clogPo/w = 4.99), questioning the 
reliability of the affinity determination by ITC and undermining any 
attempts of co-crystallization with p300 or CBP. Accordingly, the 
absolute configuration of their stereocenters and more reliable 
affinities remain unresolved. 
Consequently, we added a hydroxyl group at the C2 of the 7-
chloro-1,2,3,4-tetrahydronaphthyl moiety to increase water 
solubility, yielding XDM3 (Figure 1, cLogPo/w = 3.96). The second 
chiral center gives rise to four stereoisomers, the compounds 
XDM3a-d that were separated by means of chiral HPLC. ITC 
validation of these compounds showed good binding of p300 to 
all of them (Figure 1 and Supporting Figures S5-8). XDM3b and 
XDM3c are still recognized by CBP (Supporting Figures S6 and 
S7), while XDM3a and XDM3d failed to interact tightly with CBP 
(Supporting Figures S5 and S8). Their selectivity toward p300 
resembles that of XDM2b, suggesting that the shared absolute 
configuration of the carbon atom C1 of XDM3a and XDM3d is 
identical to the one of XDM2b. X-ray crystal structures of XDM3c 
bound to CBP and XDM3d bound to p300 (Figure 2B, Supporting 
Figure S14) allowed for the determination of the absolute 
configurations as (R,R) and (S,S), respectively. Both structures 
conserve the interaction of the 4-acyl pyrrole moiety with the KAc 
binding site. However, in CBP, flipping of the amide linker of 
XDM3c induces two slightly different positions of the 
tetrahydronaphthyl moiety, whereas in complex with p300, the 
amide of XDM3d is fixed in one orientation that forces the tail to 
address the ZA channel we initially aimed at. Here, XDM3d 
replaces a surface-bound water molecule close to Asp1080 at the 
back of the ZA channel, allowing for an interaction of its -system 
with the amide head group of Gln1077. However, Arg1137, which 
was hypothesized to form an inducible RP cavity with Pro1074, 
does not participate in binding. Rather Arg1137 appears to be 
constitutively locked in a remote position of the binding pocket by 
Tyr1141. Notably, the good discriminatory potential of XDM3d 
with respect to CBP and p300 (28-fold selectivity) does not fully 
apply to other bromodomains, in particular members of the BET 
family (Supporting Figure S9). Moreover, in the crystal structure 
we identified two additional binding modes of XDM3d to the 
surface of p300 that could not be further resolved by ITC 
(Supporting Figures S8 and S15). 
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Figure 2. Crystal structures of XDM1 and XDM3c in complex with CBP and of XDM3d bound to p300. (A) XDM1 is recognized by Asn1168 in the KAc binding 
site of CBP and stabilized by hydrogen bonds and van der Waals contacts to the hydrophobic pocket core. The 2Fo-Fc omit map at 1.0  is shown for XDM1. (B) 
Superposition of the KAc binding sites of CBP bound to XDM3c and p300 bound to XDM3d. XDM3c (yellow sticks) occupies the inducible RP cavity of CBP (yellow 
sticks and surface, shown for CBP), while XDM3d (green sticks) binds to the ZA channel of p300 (green side chains and surface, shown for p300). Differing hydrogen 
bonds and bridging waters are colored accordingly. 
In order to restrict inhibitor binding to the KAc binding site and 
to enhance specificity, we focused on improving the surface 
complementarity and supporting the -stacking by introducing a 
(naphthalene-1-yl)methyl moiety to XDM1, yielding XDM4 
(Figure 1). The hydrophobicity of this tail resulted in a weak water 
solubility, preventing successful measurements by ITC. However, 
we obtained a high-resolution crystal structure of XDM4 in 
complex with CBP (Supporting Figure S16). The 4-acyl pyrrole 
head exploits the already well-described interactions with CBP. 
The amide linker is placed like previously shown for XDM1. As 
expected, the extended aromatic tail points towards Arg1173, 
thus occupying the inducible RP cavity of CBP. 
To increase water solubility and further optimize target affinity 
by pursuing an intra-molecular hydrogen bond (IMHB), a hydroxyl 
group was introduced to the tail of XDM4, yielding XDM5 
(Figure 1). Although attempts to obtain a crystal structure of 
XDM5 in complex with either CBP or p300 were not successful, 
the affinity to p300 and to CBP was overall substantially improved 
compared to XDM3 (Figure 1, Supporting Figure S10). 
We added a second hydroxyl group to XDM5, producing 
XDM6 (Figure 1). This should allow for additional IMHBs to 
minimize the rotation of the tail. The co-crystal structures of XDM6 
with CBP and p300 reveal poses similar to previously described 
XDM4 (Figure 3). The structures confirm the establishment of two 
IMHBs between the amide linker and the novel hydroxyl groups 
of XDM6 that lock the conformation of the 2,8-
dihydroxynaphthalen-1-yl)methyl moiety (Supporting Figures S16 
and S17). This is supported by the low B-factors of this moiety 
(average B-factors of 17.8 Å2 for CBP and 18.6 Å2 for p300 with 
overall B-factors of 18.5 Å2 and 20.1 Å2, respectively, Supporting 
Table S2). A structural comparison with other CBP-inhibitor 
complexes reveals that XDM6 is the only inhibitor that is 
intrinsically fixed in a conformation that apparently induces a rigid 
rotamer fit of Arg1173 (CBP) and Arg1137 (p300, Figure 3B, 
Supporting Figure S20A). ITC analysis highlighted the benefits of 
the additional IMHB by disclosing significantly improved entropy 
contributions to binding (Supporting Figure S11A) that resulted in 
nanomolar affinities to both proteins and a ligand efficiency (LE) 
for CBP of -0.33 kcal/mol. To our knowledge, this is the highest 
LE for a nanomolar CBP inhibitor reported to date. In addition, 
XDM6 features a good lipophilic LE (LLE) of 3.22 (cLogPo/w = 
3.40), outperformed only by compound 19[9] of Unzue and co-
workers (LLE 3.56, Supporting Table S1). In addition, competition 
assays by ITC with the established CBP inhibitor I-CBP-112(3) 
show that XDM6 and I-CBP-112 address the same site in the BD 
of CBP and that their binding is mutually exclusive (Supporting 
Figure S11B-C), demonstrating that the mode of action of XDM6 
on the BD of CBP is identical to I-CBP-112. 
We next tested the specificity of XDM6 in a bromoKdELECT 
screen (DiscoveRx) against 40 BDs (Figure 4A, Supporting 
Figure S18). In comparison with the BET-inhibitor XD14,[10] the 
specificity of XDM6 is redirected from the BET family towards 
CBP/p300, having only little residual affinity to BRD9 (KD = 2.9 
M), BRD7 (KD = 4.5 M), BRD2(1), BRPF1 and BRPF3 (all close 
to 10 µM), while all other bromodomains, including BRD4(1), are 
not recognized under the test conditions (KD > 40 M). The 
avoidance of BET BDs can be assigned to the IMHBs in XDM6 
that makes a conformational change to adapt to the KAc binding 
site of BRD4(1) energetically disfavored (Supporting Figures S17 
and S20B). Hence, we name this compound XDM-CBP. 
Finally, we assessed the antiproliferative activity of XDM-CBP 
in the NCI60[13] panel provided by the National Cancer Institute 
(NCI, NIH, Rockville, MD, US). While XD14 mainly targeted 
leukemia cell lines (Supporting Figures S19 and S27), XDM-CBP 
is potent on numerous cancer variants (Figure 4B, Supporting 
Figure S26), including leukemia (mean growth inhibition at 10 M 
for 48h (GI) of 77%), breast cancer (GI = 74 %), and melanoma 
(GI = 73 %). Its potency peaks for individual cell lines of 
melanoma (SK-MEL-5), breast cancer (T-47D), and non-small 
cell lung cancer (NCI-H522).
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Figure 3. Binding of XDM-CBP to CBP and p300. (A) Recognition of XDM-CBP by CBP is driven by binding of the 4-acyl pyrrole moiety to the KAc binding site 
and by the interaction of the naphthalenyl moiety with the inducible RP cavity. (B) Superposition of the KAc binding sites of p300 (green) and CBP (yellow) in 
complex with XDM-CBP. The binding mode is largely conserved with only minor differences in the naphthalenyl position. 
A detailed analysis of the antiproliferative effect on HL-60 and 
MCF-7 cells (Supporting Figure S30) yielded GI50 values of 1.3 
µM (HL-60) and 4.2 µM (MCF-7). Here, XDM-CBP proves to be 
more efficient than I-CBP-112 in both cell lines, which might by 
due to a better LLE of XDM-CBP (LLE of 3.22) as compared to I-
CBP-112 (LLE of 2.68, Supporting Table S1). Interestingly, MCF-
7 cells remain largely unaffected by (+)-JQ1 treatment, a well 
characterized BET inhibitor,[14] supporting the discriminatory 
potential of XDM-CBP against BET BDs. 
Our results demonstrate that XDM-CBP, the final product of 
the optimization, is an excellent CBP/p300 inhibitor that combines 
outstanding ligand efficiency with high selectivity for CBP/p300 
over all other BD families, including the BET family. Most 
importantly, XDM-CBP has an antiproliferative effect on 
numerous cancer cell lines. This renders XDM-CBP a serious 
candidate for further optimization towards initial clinical studies 
and it supports the high potential of 4-acyl pyrrole derivatives for 
the development of inhibitors and therapeutic agents beyond the 
BET BD family.
Figure 4. Specificity and antiproliferative activity of XDM-CBP. (A) Phylogenetic tree of the human BD family with selectivity profiles of XDM-CBP. Sphere 
colors indicate the binding affinity to specific BDs, as observed in the BROMOscan assay. (B) Antiproliferative activity of XDM-CBP. Top: Box plot of the sensitivity 
of cancer cells covered by the NCI60 panel. Bottom: Top 5 ranked cell lines regarding sensitivity and resistance. 
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